Mirapex (pramipexole): Drug Safety Communication – Ongoing Safety Review, Possible Risk of Heart Failure

by FDA on September 19, 2012

in MedWatch

FDA currently evaluating analysis of randomized clinical trials and epidemiologic studies.

This is a summary of an alert issued by MedWatch: The FDA Safety Information and Adverse Event Reporting Program. The link below will take you to the original notice.

View Full Details Of The Original MedWatch Notice Here.

Bookmark and Share

Leave a Comment

Previous post:

Next post: